MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / News Well / Prostate cancer: Intuitive Surgical CEO Guthart on testing and “watchful waiting”

Prostate cancer: Intuitive Surgical CEO Guthart on testing and “watchful waiting”

July 24, 2012 By Arezu Sarvestani Leave a Comment

Gary Guthart Intuitive Surgical robot assisted surgery

Intuitive Surgical (NSDQ:ISRG) president & CEO Gary Guthart doesn’t believe in taking a passive approach to men’s health.

The increasingly heated conversation around the proper role of prostate cancer testing has played a big part in dragging down the market, which in turn has taken a toll on Intuitive’s numbers. But the debate can be framed rather simply from a patient perspective.

"I would rather know than not know," Guthart told MassDevice.com during an exclusive meeting at the medical device company’s Sunnyvale, Calif., headquarters yesterday. "The hear no evil, see no evil, speak no evil strategy doesn’t seem like a healthcare strategy to me."

The potential downsides of routine prostate cancer testing have gotten extra attention lately in light of the recent publication of a landmark study and a highly contested recommendation from a U.S. Preventative Services Task Force.

In May the USPSTF panel advised physicians against using a common prostate cancer screening tool, the PSA or prostate-specific antigen test, in monitoring men’s health over concerns about the dangers of aggressive treatment in patients who are asymptomatic and whose cancer may have remained neutral without intervention.

"Many people have a blind faith in early detection of cancer and subsequent aggressive medical intervention whenever cancer is found," American Cancer Society chief medical officer Dr. Otis Brawley wrote in an accompanying commentary on the panel’s decision. "There is little appreciation of the harms that screening and medical interventions can cause."

The guidance created outrage among several groups, including the Large Urology Group Practice Assn., which warned that "failing to detect cancer early will create a public health catastrophe in 5-10 years."

Although Intuitive Surgical doesn’t plan to play a big role in the public debate, the company’s stance is that testing is an important part of saving men’s lives.

"Closing your eyes and hoping there’s not a problem is probably not a good strategy," Guthart told MassDevice.com yesterday. "Having an informed conversation with a caregiver … and a long conversation about what the possibilities are for you as a person – in terms of the aggressiveness of your disease and what your comfort level is with living with something versus not – I think that is the right approach. I think that’s true of my personal opinion and I think it’s true of Intuitive’s stance."

Earlier this month the the New England Journal of Medicine published a highly anticipated decade-long study comparing surgical prostate cancer treatment to "watchful waiting," the authors of which concluded that the surgical approach “may be neither necessary nor effective” for men diagnosed with early stages of prostate cancer.

Researchers followed more than 730 men for an average of 10 years, concluding that low-risk patients who underwent radical prostatectomy were about 3% more likely to survive than men under the "wait and see" arm of the trial, regardless of age, race, comorbidity, health status or histology.

The timing of the trial and the release of the USPSTF recommendation combined may have taken an extra toll on the prostatectomy market, in which Intuitive Surgical has become the preferred option.

ISRG shares have taken a beating since the company reported softness in its da Vinci robot-assisted prostatectomy procedures during the 2nd quarter. Shares, which opened at $553.58 the morning prior to the earnings release, have since lost 14.7%, trading around $472.17 as of about 1:45 p.m. today.

"When there’s a big push like this, in the past we’ve seen people move toward active surveillance," Guthart told us. "It comes back over time."

Roughly speaking, about a third of patients who opt for "watchful waiting" stay with it, he added. Another third see their disease progress to the point of requiring intervention and the remaining third get tired of waiting and decide on more aggressive treatment.

Filed Under: News Well, Oncology, Research & Development, Robotics Tagged With: Intuitive Surgical, Prostate

In case you missed it

  • Bio-Rad recovering from ransomware attack
  • FDA clears first single-use duodenoscope from Boston Sci
  • FDA approves Tandem Diabetes’ advanced hybrid closed-loop controller
  • Awak Technologies raises $40m
  • Axonics raises additional $17m in public offering
  • Siemens Healthineers lands FDA clearance for two CT systems
  • Aethlon prices $5m offering
  • Sterigenics’ legal troubles mount in Illinois
  • In2Bones launches AlloAid BioNail
  • Caresyntax to acquire Syus; raises $45.6m
  • Nihon Kohden launches new patient monitor
  • Senate confirms Dr. Stephen Hahn to lead FDA
  • Iradimed renews CE mark for MRI-safe patient monitor
  • Flexicare recalls fiber optic laryngoscope blades and handles
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
  • TransEnterix announces reverse split of common stock
  • GI Windows raises $15m Series A

RSS From Medical Design & Outsourcing

  • Siemens Healthineers lands FDA clearance for two CT systems
    Siemens Healthineers this week said it won FDA clearance for its Somatom go.Sim and Somtom go.Open Pro computed tomography systems. The CT systems are designed for radiation therapy planning and are members of the company’s Somatom go. platform of devices. Siemens Healthineers’ platform uses hardware and software components like patient marking lasers and automated quality… […]
  • Protolabs’ healthcare grant spurs 2 feeding tube inventions
    Digital manufacturer Protolabs (NYSE:PRLB) announced today that MedStar Health (Columbia, Md.) and Cleveland Clinic Innovations are joint winners of the company’s Cool Idea Award: Healthcare Grant. These grants provide in-kind manufacturing services to the support development of medical products to spur innovation in the field. MedStar Health’s gravity-feed syringe holder simplifies the feeding of newborns who spend […]
  • Sterigenics’ legal troubles mount in Illinois
    Nearly two dozen new lawsuits were filed against Sterigenics this week over its now-shuttered ethylene oxide (EtO) sterilization plant in Willowbrook, Ill., according to a law firm representing some of the plaintiffs. That brings the total of such lawsuits to nearly 75, noted Chicago personal injury lawyer Antonio Romanucci, court-appointed lead counsel from among five… […]
  • In2Bones launches AlloAid BioNail
    In2Bones this week launched its AlloAid BioNail sterile allograft implant. The implant is designed to give rigid, stable fixation during hand and foot reconstruction. AlloAid BioNail is made from strong cortical allografts to provide osteoconductive properties for bone remodeling and healing. It features a tapered point and multiple, contoured wedge facets to ease insertion, anchor… […]
  • Protolabs’ healthcare grant spurs 2 feeding tube inventions
    Digital manufacturer Protolabs (NYSE:PRLB) announced today that MedStar Health (Columbia, Md.) and Cleveland Clinic Innovations are joint winners of the company’s Cool Idea Award: Healthcare Grant. These grants provide in-kind manufacturing services to the support development of medical products to spur innovation in the field. MedStar Health’s gravity-feed syringe holder simplifies the feeding of newborns… […]
  • Nihon Kohden launches new patient monitor
    Nihon Kohden (TYO:6849) announced the U.S. launch of its Life Scope SVM-7200 series vital signs monitor for outpatient facilities and beds that aren’t continuously monitored. The Life Scope SVM-7200 is designed to provide customizable early warning scoring to help clinicians identify patients who are deteriorating or at risk of deterioration. It combines vital signs data with… […]
  • Senate confirms Dr. Stephen Hahn to lead FDA
    The U.S. Senate has confirmed Dr. Stephen Hahn as the next commissioner of the FDA. The vote was 72 to 18, according to a report in the New York Times. Hahn will be the first permanent commissioner of the agency since Dr. Scott Gottlieb resigned in April. President Trump nominated Hahn, the chief medical officer at Houston’s… […]
  • 3M to sell drug-delivery biz to Altaris Capital Partners for $650m
    3M (NYSE:MMM) announced today that it entered into an agreement to sell most of its drug-delivery business to an affiliate of Altaris Capital Partners for approximately $650 million. St. Paul, Minn.-based 3M will retain its transdermal drug delivery components business, according to a news release. The business being divested has annual global sales reaching approximately… […]
  • Lawsuit endangers Sterigenics consent order in Georgia
    A consent order that Sterigenics entered into with the state of Georgia to reduce ethylene oxide (EtO) emissions at its Atlanta medtech sterilization plant may be in jeopardy. A hearing is scheduled today on a lawsuit that accuses the Georgia Environmental Protection Division (EPD) of failing to take public comment before entering the Aug. 7… […]
  • Trelleborg acquires Tritec Seal
    Trelleborg Sealing Solutions said today it has closed on its acquisition of rotary seal manufacturer Tritec Seal, which produces engineered polytetrafluoroethylene (PTFE) sealing solutions. Trelleborg said the acquisition strengthens its product portfolio while giving the business area access to increased manufacturing capacity. Headquartered in Fenton, Mich., with additional manufacturing in Giddings, Texas, Tritec Seal generated… […]
  • RSNA 2019: 7 radiology innovations you need to know
    Nearly 53,000 people attended the 2019 Radiological Society of North America annual meeting in Chicago last week. And they heard the same acronym over and over again: AI. Exhibitors at the conference touted their artificial-intelligence-enhanced technology at every turn, claiming to make images clearer, sharper, easier to use and powerful enough to help clinicians make… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS